Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk
NCT ID: NCT01727349
Last Updated: 2021-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1035 participants
INTERVENTIONAL
2011-12-14
2020-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Until now, efforts have been concentrated on individuals at risk for diabetes readily identifiable within the general population, typically subjects in the second half of adulthood, presenting abdominal obesity and mild abnormalities of blood sugar. Preventive lifestyle and dietary measures are proposed but are constrictive and difficult to maintain over time, and the results, although they may be significant, remain disappointing, with mere postponement of an outcome which at this stage appears inevitable. The reason is ascribable to excessively tardy intervention, when the pathogenic process has already been ongoing for some ten years and the endocrine function of the pancreas is probably already irreparably impaired.
The alternative thus is earlier intervention, in childhood, adolescence or early adulthood. The problem is to identify individuals at high risk of becoming diabetic at a time when they are presenting no simple clinical or laboratory abnormalities allowing easy diagnosis. The familial character of type 2 diabetes is now well established, and future diabetic subjects are themselves above all the children of diabetic subjects. However, the prevalence of the disease among the descendants of type 2 diabetic subjects is around 20-30% and predictive tools are needed to combat diabetes in these high-risk families.
We propose to create a risk equation using an algorithm to reliably predict children most likely to develop diabetes later in life.
The algorithm will include 3 classes of data:
* The genotype stemming from the genetic characterization of individuals and those their parents;
* Environmental data concerning childhood, especially eating habits and physical activity;
* Data of the mother who was eventually diabetic during pregnancy.
From a methodological standpoint, it would be rather difficult to take blood samples from children and wait some 50 years to determine whether or not they develop diabetes. To circumvent this difficulty, we will recruit subjects in families with a history of type II diabetes:
* Parents alive, including at least one type 2 diabetic subject
* Adult children (aged over 35 years), some of whom are already presenting type II diabetes, and healthy brothers and sisters, who form the control population. Test will be done to determine whether healthy subjects are really safe from the risk of diabetes (HbA1c measurement and glucose load test).
The Descendence study will include 500 families at risk involving about 3000 subjects (1000 subjects with diabetes and 2000 healthy subjects). It is expected to answer the following question: for a child born in such families at risk, what is the probability of developing diabetes later in life, so that early preventive action may be taken
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relationship Between Gestational Diabetes and Type 2 Diabetes
NCT01340924
Continuous Glucose Monitoring System Feasibility in Youth With T2D
NCT06089070
Time Spent In Target Glucose Range in Women With T2D Diabetes in Pregnancy
NCT06147466
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
NCT03620357
Oral Glucose Tolerance Test and Post Partum Diagnosis of Diabetes Mellitus, Type 2 (DT2 Post-Partum)
NCT03644004
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type 2 diabetic subject
Subject with type 2 diabetes
HbA1c measurement
healthy subject
Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
Oral Glucoce Tolerance Test
Oral Glucoce Tolerance Test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HbA1c measurement
Oral Glucoce Tolerance Test
Oral Glucoce Tolerance Test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must be aged over 25 years
Exclusion Criteria
* pregnant women
25 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Sart Tilman Liège
Liège, , Belgium
CHU Jean Minjoz
Besançon, , France
CHU Avicenne
Bobigny, , France
CHU de Bondy
Bondy, , France
CHU de BREST
Brest, , France
CHU de Caen
Caen, , France
CH Sud Francilien
Évry, , France
University Hospital Grenoble
Grenoble, , France
CHU de Bicetre
Le Kremlin-Bicêtre, , France
CHRU Lille
Lille, , France
CHU Marseille Hôpitaux Sud
Marseille, , France
CHU de Nancy
Nancy, , France
CHU de Nantes
Nantes, , France
CHU Bichat
Paris, , France
CHU de REIMS
Reims, , France
Centre Hospitalier Strasbourg
Strasbourg, , France
CHU Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-A00686-35
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.